Moventig (Naloxegol)

Naloxegol selectively blocks peripheral μ‑opioid receptors located in the gut. By preventing opioids from binding to these receptors, it restores normal intestinal motility and fluid secretion, thereby relieving constipation without affecting the central pain‑relieving actions of the opioid.

The appropriate dose of Moventig is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal and hepatic function, and concomitant medications. Dosing is typically once daily, and the prescriber may adjust the regimen as needed.

Limited clinical data are available for naloxegol use during pregnancy or lactation. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss alternatives with their healthcare provider.

To order Moventig, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request verification of trade or institutional credentials. After confirmation, the team provides pricing, availability, shipping details (including any cold‑chain requirements) and assists with import documentation.

Moventig (naloxegol) belongs to the PAMORA class, which directly antagonizes peripheral opioid receptors. An alternative PAMORA, methylnaltrexone, is administered by injection and also blocks peripheral receptors. Non‑PAMORA options such as lubiprostone or linaclotide work via different mechanisms (chloride channel activation or guanylate cyclase‑C activation) and may be less effective in patients on high‑dose opioids.

Moventig should be stored below 25 °C in its original packaging, protected from moisture and direct sunlight. Keep the product out of reach of children and do not use after the expiry date printed on the label.

Moventig is taken orally, usually with a full glass of water. It can be taken with or without food, but patients should follow the specific instructions provided by their prescriber. Swallow the tablet whole; do not crush, chew, or split it unless directed by a healthcare professional.

The most serious risks include intestinal obstruction or severe abdominal pain, which may indicate a serious gastrointestinal event, and hypersensitivity reactions such as rash, pruritus, or anaphylaxis. Patients should seek immediate medical attention if they experience persistent severe abdominal discomfort, vomiting, or signs of an allergic reaction.

Moventig should not be used in patients with known or suspected gastrointestinal obstruction, severe hepatic impairment (Child‑Pugh class C), or in those taking strong CYP3A4 inhibitors such as ketoconazole or clarithromycin. It is also contraindicated in individuals with a history of hypersensitivity to naloxegol or any of its excipients.